J.P. Morgan is out with its report today on Exelexis EXEL, maintaining Neutral.
In a note to clients, J.P. Morgan writes, "We are maintaining our Neutral rating on EXEL following a tumultuous ASCO
meeting. On the positive side, we are increasingly impressed by the striking bone met effects of cabozantinib with each incremental data update, and we gathered promising physician feedback on the CRPC data. However, that
optimism is somewhat offset by an increasingly competitive prostate cancer landscape that further muddies the optimal regulatory path (and commercial outlook) for cabo in our view, and to a lesser extent by safety concerns that could
linger as an overhang."
J.P. Morgan maintains a $10 PT on EXEL.
Shares of EXEL closed Tuesday at $9.76, up 12.31% from Monday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in